Latest Healthcare News

Elanor Investors Group has finalised a $125 million recapitalisation that slashes its cost of capital and reduces debt, setting the stage for a leaner, capital-light funds management model and imminent ASX reinstatement.

LTR Pharma has secured a binding US telehealth commercialisation framework for its intranasal erectile dysfunction treatment ROXUS, committing to at least 150,000 prescriptions in the first year and granting exclusivity to Shed Holdings' platform.

Ryman Healthcare has opened a NZ$100 million fixed rate bond offer maturing in 2032, featuring an exchange mechanism for existing bondholders and a minimum interest rate of 5.60%. The offer targets institutional and retail investors and aims to refinance debt and diversify funding.

Ryman Healthcare has launched a NZ$100 million fixed rate bond offer maturing in 2032, aiming to refinance existing debt and diversify its funding sources. The offer includes an exchange mechanism for existing bondholders, with trading in current bonds to be suspended during the transition.

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.

Ryman Healthcare nearly doubles operating profitability and generates positive free cash flow for the first time in over a decade, while shifting strategy toward sustainable growth and targeting dividend returns by FY28.

dorsaVi reveals that integrating RRAM and neuromorphic computing into its sensor platform could halve sensor count and more than double battery life in lower-limb exoskeletons, positioning the company as a key intelligence partner in a $1.79 billion market.

EBR Systems has secured a significant regulatory milestone as the US Centers for Medicare & Medicaid Services (CMS) initiates a National Coverage Determination (NCD) for its WiSE wireless cardiac pacing system, aiming for approval by early 2027.

Careteq Limited’s strategic investor Antanas Guoga has converted all his convertible notes into shares, wiping out the company’s convertible debt and simplifying its capital structure ahead of its AI healthtech growth push.

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Pro Medicus' U.S. subsidiary Visage Imaging has extended its contract with The Ohio State University Wexner Medical Center for five years, adding new Visage 7 modules and increasing transaction fees, underpinning strong client retention and platform demand.